Design, synthesis, preliminary pharmacological evaluation, and docking studies of pyrazoline derivatives

[1] Amnerkar, N. D., & Bhusari, K. P. (2010). Synthesis, anticonvulsant activity and 3D-QSAR study of some prop-2-eneamido and 1-acetyl-pyrazolin derivatives of aminoben zothiazole. European Journal of Medicinal Chemistry, 45, 149–159. DOI: 10.1016/j.ejmech.2009.09.037. http://dx.doi.org/10.1016/j.ejmech.2009.09.03710.1016/j.ejmech.2009.09.037Search in Google Scholar PubMed

[2] Amr, A. E. E., Abdel-Latif, N. A., & Abdalla, M. M. (2006). Synthesis and antiandrogenic activity of some new 3-substituted androstano[17,16-c]-5′-aryl-pyrazoline and their derivatives. Bioorganic & Medicinal Chemistry, 14, 373–384. DOI: 10.1016/j.bmc.2005.08.024. http://dx.doi.org/10.1016/j.bmc.2005.08.02410.1016/j.bmc.2005.08.024Search in Google Scholar PubMed

[3] Bourin, M., Hascoët, M., Colombel, M. C., Coutts, R. T., & Baker, G. B. (2002). Clonidine potentiates the effects of tranylcypromine, phenelzine and two analogues in the forced swimming test in mice. Journal of Psychiatry & Neuroscience, 27, 178–185. Search in Google Scholar

[4] Casimiro-Garcia, A., Dudley, D. A., Heemstra, R. J., Filipski, K. J., Bigge, C. F., & Edmunds, J. J. (2006). Progress in the discovery of factor Xa inhibitors. Expert Opinion on Therapeutic Patents, 16, 119–145. DOI: 10.1517/13543776.16.2.119. http://dx.doi.org/10.1517/13543776.16.2.11910.1517/13543776.16.2.119Search in Google Scholar

[5] Chimenti, F., Bolasco, A., Manna, F., Secci, D., Chimenti, P., Befani, O., Turini, P., Giovannini, V., Mondovì, B., Cirilli, R., & La Torre, F. (2004). Synthesis and selective inhibitory activity of 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives against monoamine oxidase. Journal of Medicinal Chemistry, 47, 2071–2074. DOI: 10.1021/jm031042b. http://dx.doi.org/10.1021/jm031042b10.1021/jm031042bSearch in Google Scholar PubMed

[6] Chimenti, F., Carradori, S., Secci, D., Bolasco, A., Bizzarri, B., Chimenti, P., Granese, A., Yáñez, M., & Orallo, F. (2010). Synthesis and inhibitory activity against human monoamine oxidase of N1-thiocarbamoyl-3,5-di(hetero)aryl-4,5-dihydro-(1H)-pyrazole derivatives. European Journal of Medicinal Chemistry, 45, 800–804. DOI: 10.1016/j.ejmech.2009.11.003. http://dx.doi.org/10.1016/j.ejmech.2009.11.00310.1016/j.ejmech.2009.11.003Search in Google Scholar PubMed

[7] Chimenti, F., Fioravanti, R., Bolasco, A., Manna, F., Chimenti, P., Secci, D., Rossi, F., Turini, P., Ortuso, F., Alcaro, S., & Cardia, M. C. (2008). Synthesis, molecular modeling studies and selective inhibitory activity against MAO of N1-propanoyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives. European Journal of Medicinal Chemistry, 43, 2262–2267. DOI: 10.1016/j.ejmech.2007.12.026. http://dx.doi.org/10.1016/j.ejmech.2007.12.02610.1016/j.ejmech.2007.12.026Search in Google Scholar PubMed

[8] De Colibus, L., Li, M., Binda, C., Lustig, A., Edmondson, D. E., & Mattevi, A. (2005). Three-dimensional structure of human monoamine oxidase A (MAO A): relation to the structures of rat MAO A and human MAO B. Proceedings of the National Academy of Sciences USA, 102, 12684–12689. DOI: 10.1073/pnas.0505975102. http://dx.doi.org/10.1073/pnas.050597510210.1073/pnas.0505975102Search in Google Scholar PubMed PubMed Central

[9] El-Wahab, A. H. F. A., Al-Fifi, Z. I. A., Bedair, A. H., Ali, F. M., Halawa, A. H. A., & El-Agrody, A. M. (2011). Synthesis, reactions and biological evaluation of some new naphtho[2,1-b]furan derivatives bearing a pyrazole nucleus. Molecules, 16, 307–318. DOI: 10.3390/molecules16010307. http://dx.doi.org/10.3390/molecules1601030710.3390/molecules16010307Search in Google Scholar PubMed PubMed Central

[10] Fioravanti, R., Bolasco, A., Manna, F., Rossi, F., Orallo, F., Ortuso, F., Alcaro, S., & Cirilli, R. (2010). Synthesis and biological evaluation of N-substituted-3,5-diphenyl-2-pyrazoline derivatives as cyclooxygenase (COX-2) inhibitors. European Journal of Medicinal Chemistry, 45, 6135–6138. DOI: 10.1016/j.ejmech.2010.10.005. http://dx.doi.org/10.1016/j.ejmech.2010.10.00510.1016/j.ejmech.2010.10.005Search in Google Scholar PubMed

[11] Fowler, J. S., Logan, J., Azzaro, A. J., Fielding, R. M., Zhu, W., Poshusta, A. K., Burch, D., Brand, B., Free, J., Asgharnejad, M., Wang, G. J., Telang, F., Hubbard, B., Jayne, M., King, P., Carter, P., Carter, S., Xu, Y., Shea, C., Muench, L., Alexoff, D., Shumay, E., Schueller, M., Warner, D., & Apelskog-Torres, K. (2010). Reversible inhibitors of monoamine oxidase-A (RIMAs): robust, reversible inhibition of human brain MAO-A by CX157. Neuropsychopharmacology, 35, 623–631. DOI: 10.1038/npp.2009.167. http://dx.doi.org/10.1038/npp.2009.16710.1038/npp.2009.167Search in Google Scholar PubMed PubMed Central

[12] Gok, S., Demet, M. M., Özdemir, A., & Turan-Zitouni, G. (2010). Evaluation of antidepressant-like effect of 2-pyrazoline derivatives. Medicinal Chemistry Research, 19, 94–101. DOI: 10.1007/s00044-009-9176-x. http://dx.doi.org/10.1007/s00044-009-9176-x10.1007/s00044-009-9176-xSearch in Google Scholar

[13] Halgren, T. A., Murphy, R. B., Friesner, R. A., Beard, H. S., Frye, L. L., Pollard, W. T., & Banks, J. L. (2004). Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. Journal of Medicinal Chemistry, 47, 1750–1759. DOI: 10.1021/jm030644s. http://dx.doi.org/10.1021/jm030644s10.1021/jm030644sSearch in Google Scholar

[14] Jia, Z., & Zhu, Q. (2010). ’Click’ assembly of selective inhibitors for MAO-A. Bioorganic & Medicinal Chemistry Letters, 20, 6222–6225. DOI: 10.1016/j.bmcl.2010.08.104. http://dx.doi.org/10.1016/j.bmcl.2010.08.10410.1016/j.bmcl.2010.08.104Search in Google Scholar

[15] Kaplancikli, Z. A., Özdemir, A., Turan-Zitouni, G., Altintop, M. D., & Can, O. D. (2010). New pyrazoline derivatives and their antidepressant activity. European Journal of Medicinal Chemistry, 45, 4383–4387. DOI: 10.1016/j.ejmech.2010.06.011. http://dx.doi.org/10.1016/j.ejmech.2010.06.01110.1016/j.ejmech.2010.06.011Search in Google Scholar

[16] Karuppasamy, M., Mahapatra, M., Yabanoglu, S., Ucar, G., Sinha, B. N., Basu, A., Mishra, N., Sharon, A., Kulandaivelu, U., & Jayaprakash, V. (2010). Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies. Bioorganic & Medicinal Chemistry, 18, 1875–1881. DOI: 10.1016/j.bmc.2010.01.043. http://dx.doi.org/10.1016/j.bmc.2010.01.04310.1016/j.bmc.2010.01.043Search in Google Scholar

[17] Krall, R. L., Penry, J. K., White, B. G., Kupferberg, H. J., & Swinyard, E. A. (1978). Antiepileptic drug development: II. Anticonvulsant drug screening. Epilepsia, 19, 409–428. DOI: 10.1111/j.1528-1157.1978.tb04507.x. http://dx.doi.org/10.1111/j.1528-1157.1978.tb04507.x10.1111/j.1528-1157.1978.tb04507.xSearch in Google Scholar

[18] Manna, F., Chimenti, F., Bolasco, A., Secci, D., Bizzarri, B., Befani, O., Turini, P., Mondovi, B., Alcaro, S., & Tafi, A. (2002). Inhibition of amine oxidases activity by 1-acetyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives. Bioorganic & Medicinal Chemistry Letters, 12, 3629–3633. DOI: 10.1016/S0960-894X(02)00699-6. http://dx.doi.org/10.1016/S0960-894X(02)00699-610.1016/S0960-894X(02)00699-6Search in Google Scholar

[19] Motulsky, H. (1984). GraphPad InStat version 3.01 for Windows 95 (GraphPad software). San Diego, CA, USA: GraphPad Software, Inc. Search in Google Scholar

[20] Ozdemir, Z., Kandilci, H. B., Gumusel, B., Calis, U., & Bilgin, A. A. (2008). Synthesis and studies on antidepressant and anticonvulsant activities of some 3-(2-thienyl) pyrazoline derivatives. Archiv der Pharmazie, 341, 701–707. DOI: 10.1002/ardp.200800068. http://dx.doi.org/10.1002/ardp.20080006810.1002/ardp.200800068Search in Google Scholar PubMed

[21] Petit-Demouliere, B., Chenu, F., & Bourin, M. (2005). Forced swimming test in mice: a review of antidepressant activity. Psychopharmacology, 177, 245–255. DOI: 10.1007/s00213-004-2048-7. http://dx.doi.org/10.1007/s00213-004-2048-710.1007/s00213-004-2048-7Search in Google Scholar PubMed

[22] Porsolt, R. D., Bertin, A., & Jalfre, M. (1977). Behavioral despair in mice: a primary screening test for antidepressants. Archives Internationales de Pharmacodynamie et de Thérapie, 229, 327–336. Search in Google Scholar

[23] Prasad, Y. R., Rao, A. L., Prasoona, L., Murali, K., & Kumar, P. R. (2005). Synthesis and antidepressant activity of some 1,3,5-triphenyl-2-pyrazolines and 3-(2″-hydroxy naphthalen-1″-yl)-1,5-diphenyl-2-pyrazolines. Bioorganic & Medicinal Chemistry Letters, 15, 5030–5034. DOI: 10.1016/j.bmcl.2005.08.040. http://dx.doi.org/10.1016/j.bmcl.2005.08.04010.1016/j.bmcl.2005.08.040Search in Google Scholar PubMed

[24] Rani, M., Yusuf, M., Khan, S. A., Sahota, P. P., & Pandove, G. (2011). Synthesis, studies and in-vitro antibacterial activity of N-substituted 5-(furan-2-yl)-phenyl pyrazolines. Arabian Journal of Chemistry, in press. DOI: 10.1016/j.jscs.2011.02.012. 10.1016/j.jscs.2011.02.012Search in Google Scholar

[25] Siddiqui, N., Alam, P., & Ahsan, W. (2009). Design, synthesis, and in-vivo pharmacological screening of N,3-(substituted diphenyl)-5-phenyl-1H-pyrazoline-1-carbothioamide derivatives. Archiv der Pharmazie, 342, 173–181. DOI: 10.1002/ardp.200800130. http://dx.doi.org/10.1002/ardp.20080013010.1002/ardp.200800130Search in Google Scholar PubMed

[26] Vogel, H. G. (2002). Rotarod method. In Drug discovery and evaluation: Pharmacological assays (pp. 398). New York, NY, USA: Springer. http://dx.doi.org/10.1007/3-540-29837-110.1007/3-540-29837-1Search in Google Scholar

[27] Youdim, M. B. H., Edmondson, D., & Tipton, K. F. (2006). The therapeutic potential of monoamine oxidase inhibitors. Nature Reviews Neuroscience, 7, 295–309. DOI: 10.1038/nrn-1883. http://dx.doi.org/10.1038/nrn1883Search in Google Scholar